Genetic Risk scoring can predict adverse outcomes in #SLE #EULAR2024 @RheumNow https://t.co/g9kGdRkCOh

• https://twitter.com/bella_mehta/status/1800908568084041764/photo/1

Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased preeclampsia when they have LN #EULAR2024 Abst#0986 @RheumNow

Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and #humanintellegence #EULAR2024 @Lupusreference @RheumNow https://t.co/1aN8QPgVWn

• https://twitter.com/bella_mehta/status/1800896316337516653/photo/1
• https://twitter.com/bella_mehta/status/1800896316337516653/photo/1

Treat to target in #lupus - difficult for many reasons. Also may be too much of a restrictive strategy. @Lupusreference talks about DORIS definition of remission- however mentions may be difficult to do in daily practice #EULAR2024 @rheumnow https://t.co/XqiubfOz2n

• https://twitter.com/bella_mehta/status/1800894658689847372/photo/1
• https://twitter.com/bella_mehta/status/1800894658689847372/photo/1
• https://twitter.com/bella_mehta/status/1800894658689847372/photo/1
• https://twitter.com/bella_mehta/status/1800894658689847372/photo/1

Many drugs in the horizon for #lupus @Lupusreference lecture #EULAR2024 Loved the timeline of all major drug -phase 2 and 3 drugs. Need for new strategies in Lupus – outcomes and survival is plateauing! @RheumNow https://t.co/Ue239woQJr

• https://twitter.com/bella_mehta/status/1800892882716655839/photo/1
• https://twitter.com/bella_mehta/status/1800892882716655839/photo/1
• https://twitter.com/bella_mehta/status/1800892882716655839/photo/1
• https://twitter.com/bella_mehta/status/1800892882716655839/photo/1

Clinical pearl in #SLE pregnancies #EULAR2024 Whats new in lupus session. Measure Hydroxychloroquine levels! @RheumNow https://t.co/OnktkMSPR5

• https://twitter.com/bella_mehta/status/1800891966944948495/photo/1

Lupus GPT - a chatbot which is much more relevant to Lupus - for patients and physician question etc. #EULAR2024 - Will be functional soon. Looking forward to playing with this. #LLMs #ChatGPT More to come. @RheumNow https://t.co/mGXG6A85Hx

• https://twitter.com/bella_mehta/status/1800891591911166202/photo/1

Biomarkers in Lupus - Urine biomarkers @andreafava in #EULAR2024 We need these biomarkers to come in mainstream clinical practice if they work better than proteinuria. @RheumNow https://t.co/i7aeBx6qRR

• https://twitter.com/bella_mehta/status/1800889999401062636/photo/1

@Lupusreference noted data suggests pulse IV methylprednisolone yields better outcomes for LN than adjustments of chronic oral steroids. #EULAR24 @RheumNow https://t.co/n93x036uIn

• https://twitter.com/KDAO2011/status/1800889681359642799/photo/1

Precision medicine in Lupus is far from reality today. @Lupusreference @RheumNow #EULAR2024

Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls. Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids) @RheumNow https://t.co/Fz1dZUVomF

• https://twitter.com/bella_mehta/status/1800888908831674721/photo/1
• https://twitter.com/bella_mehta/status/1800888908831674721/photo/1

Should we treat to target (T2T) for #SLE or just do SOC and gestalt (as most do in clinical practice)? @Lupusreference #EULAR24 @RheumNow

Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24

Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI

• https://twitter.com/KDAO2011/status/1800873281085710534/photo/1

🌎 Global disparities in steroid prescribing in #SLE 💊 HCQ assoc with decreased steroid use 📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics 📍SLE poster tour 15:30 TODAY #EULAR2024 Abs #POS0013 @RheumNow https://t.co/7pL8kpeqOs

• https://twitter.com/DrMiniDey/status/1800833564180963574/photo/1